⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL390686 | 1.00 | — | — | |
| Ammonia Solution, Strong SCHEMBL11877468 | 1.00 | — | — | |
| Bromide SCHEMBL30818314 | 0.93 | — | — | |
| SCHEMBL2143459 | 0.91 | — | — | |
| SCHEMBL1168 | 0.91 | — | — | |
| SCHEMBL18916 | 0.91 | — | — | |
| SCHEMBL53946 | 0.91 | — | — | |
| SCHEMBL6060607 | 0.91 | — | — | |
| SCHEMBL10489172 | 0.91 | — | — | |
| SCHEMBL2143464 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018195-A1 | CHIMERIC IMMUNOGENIC POLYPEPTIDES | RESEARCH DEVELOPMENT FOUNDATION (US) | 2024-01-18 | — | — | US | claimed |
| US-20230210973-A1 | PROTEINS AND NUCLEIC ACIDS FOR EHRLICHIA DIAGNOSIS AND VACCINATION | RESEARCH DEVELOPMENT FOUNDATION (US) | 2023-07-06 | — | — | US | claimed |
| EP-4146230-A1 | PROTEINS AND NUCLEIC ACIDS FOR EHRLICHIA DIAGNOSIS AND VACCINATION | Research Development Foundation (US) | 2023-03-15 | — | — | EP | claimed |
| US-20220356231-A1 | EHRLICHIA VACCINES AND IMMUNOGENIC COMPOSITIONS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2022-11-10 | — | — | US | claimed |
| EP-3996741-A1 | EHRLICHIA VACCINES AND IMMUNOGENIC COMPOSITIONS | Research Development Foundation (US) | 2022-05-18 | — | — | EP | claimed |
| WO-2021226572-A1 | PROTEINS AND NUCLEIC ACIDS FOR EHRLICHIA DIAGNOSIS AND VACCINATION | RESEARCH DEVELOPMENT FOUNDATION (US) | 2021-11-11 | — | — | WO | claimed |
| US-20210292377-A1 | CHIMERIC IMMUNOGENIC POLYPEPTIDES | RESEARCH DEVELOPMENT FOUNDATION (US) | 2021-09-23 | — | — | US | claimed |
| EP-3830105-A1 | CHIMERIC IMMUNOGENIC POLYPEPTIDES | Research Development Foundation (US) | 2021-06-09 | — | — | EP | claimed |
| WO-2021011456-A1 | EHRLICHIA VACCINES AND IMMUNOGENIC COMPOSITIONS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2021-01-21 | — | — | WO | claimed |
| WO-2020023950-A1 | CHIMERIC IMMUNOGENIC POLYPEPTIDES | RESEARCH DEVELOPMENT FOUNDATION (US) | 2020-01-30 | — | — | WO | claimed |
| US-20240018195-A1 | CHIMERIC IMMUNOGENIC POLYPEPTIDES | RESEARCH DEVELOPMENT FOUNDATION (US) | 2024-01-18 | — | — | US | disclosed |
| US-11780892-B2 | Chimeric immunogenic polypeptides | RESEARCH DEVELOPMENT FOUNDATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230210973-A1 | PROTEINS AND NUCLEIC ACIDS FOR EHRLICHIA DIAGNOSIS AND VACCINATION | RESEARCH DEVELOPMENT FOUNDATION (US) | 2023-07-06 | — | — | US | disclosed |
| EP-4146230-A1 | PROTEINS AND NUCLEIC ACIDS FOR EHRLICHIA DIAGNOSIS AND VACCINATION | Research Development Foundation (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20220356231-A1 | EHRLICHIA VACCINES AND IMMUNOGENIC COMPOSITIONS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2022-11-10 | — | — | US | disclosed |
| US-8790660-B2 | Vaccine against Ehrlichia canis | INTERVET INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130224247-A1 | VACCINE AGAINST EHRLICHIA CANIS | INTERVET INC. | 2013-08-29 | — | — | US | disclosed |
| EP-2588133-A2 | VACCINE AGAINST EHRLICHIA CANIS AND ASSOCIATED METHODS | Intervet International B.V. (NL) | 2013-05-08 | — | — | EP | disclosed |
| EP-2433646-A1 | Vaccine against Ehrlichia canis and associated methods | Intervet International BV (NL) | 2012-03-28 | — | — | EP | disclosed |
| WO-2012003205-A2 | VACCINE AGAINST EHRLICHIA CANIS AND ASSOCIATED METHODS | INTERVET INTERNATIONAL B.V. (NL) | 2012-01-05 | — | — | WO | disclosed |